Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Sold by Blue Trust Inc.

Blue Trust Inc. trimmed its holdings in Medpace Holdings, Inc. (NASDAQ:MEDPFree Report) by 17.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 565 shares of the company’s stock after selling 116 shares during the quarter. Blue Trust Inc.’s holdings in Medpace were worth $173,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently bought and sold shares of the company. McGlone Suttner Wealth Management Inc. purchased a new stake in shares of Medpace in the 4th quarter valued at approximately $33,000. Procyon Advisors LLC grew its stake in Medpace by 11.8% in the fourth quarter. Procyon Advisors LLC now owns 2,388 shares of the company’s stock valued at $732,000 after purchasing an additional 252 shares in the last quarter. Portside Wealth Group LLC grew its stake in Medpace by 14.8% in the fourth quarter. Portside Wealth Group LLC now owns 1,419 shares of the company’s stock valued at $435,000 after purchasing an additional 183 shares in the last quarter. Raymond James Financial Services Advisors Inc. acquired a new position in Medpace in the fourth quarter worth approximately $322,000. Finally, Raymond James & Associates increased its stake in shares of Medpace by 15.1% during the 4th quarter. Raymond James & Associates now owns 47,009 shares of the company’s stock worth $14,410,000 after purchasing an additional 6,177 shares during the last quarter. 77.98% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, Director Ashley M. Keating sold 250 shares of the firm’s stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $409.87, for a total transaction of $102,467.50. Following the sale, the director now owns 250 shares of the company’s stock, valued at approximately $102,467.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Medpace news, VP Susan E. Burwig sold 102 shares of the company’s stock in a transaction that occurred on Friday, March 15th. The stock was sold at an average price of $403.00, for a total transaction of $41,106.00. Following the completion of the transaction, the vice president now owns 15,181 shares of the company’s stock, valued at approximately $6,117,943. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Ashley M. Keating sold 250 shares of the stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $409.87, for a total transaction of $102,467.50. Following the transaction, the director now owns 250 shares of the company’s stock, valued at approximately $102,467.50. The disclosure for this sale can be found here. Insiders sold a total of 189,340 shares of company stock valued at $76,651,647 in the last ninety days. 25.70% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on MEDP shares. Deutsche Bank Aktiengesellschaft started coverage on Medpace in a report on Monday, March 18th. They set a “hold” rating and a $395.00 price objective on the stock. StockNews.com cut shares of Medpace from a “buy” rating to a “hold” rating in a research note on Saturday, March 23rd. Robert W. Baird increased their price objective on Medpace from $312.00 to $408.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 14th. Finally, UBS Group raised shares of Medpace from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $282.00 to $452.00 in a research note on Thursday, February 15th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $382.00.

View Our Latest Research Report on Medpace

Medpace Trading Down 1.5 %

MEDP opened at $397.99 on Tuesday. Medpace Holdings, Inc. has a 1-year low of $185.43 and a 1-year high of $419.42. The firm has a 50-day moving average price of $370.59 and a two-hundred day moving average price of $307.03. The stock has a market capitalization of $12.24 billion, a PE ratio of 44.82, a PEG ratio of 2.14 and a beta of 1.38.

Medpace (NASDAQ:MEDPGet Free Report) last announced its quarterly earnings data on Monday, February 12th. The company reported $2.46 earnings per share for the quarter, beating the consensus estimate of $2.22 by $0.24. Medpace had a net margin of 15.00% and a return on equity of 63.98%. The business had revenue of $498.40 million for the quarter, compared to analyst estimates of $498.72 million. During the same period in the prior year, the business posted $2.12 earnings per share. Medpace’s revenue was up 26.5% compared to the same quarter last year. On average, research analysts predict that Medpace Holdings, Inc. will post 10.53 EPS for the current year.

About Medpace

(Free Report)

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.

Featured Articles

Institutional Ownership by Quarter for Medpace (NASDAQ:MEDP)

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.